Phase IV Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis
Latest Information Update: 14 Mar 2025
At a glance
- Drugs Secukinumab (Primary)
- Indications Psoriasis
- Focus Therapeutic Use
Most Recent Events
- 11 Mar 2025 Planned End Date changed from 1 Dec 2025 to 1 Jun 2025.
- 11 Mar 2025 Planned primary completion date changed from 1 Dec 2025 to 1 Jun 2025.
- 11 Mar 2025 Status changed from recruiting to active, no longer recruiting.